Pfizer's Updated COVID Shot Ships Into a Market 93% Smaller Than Its Peak

On Thursday the FDA cleared Pfizer and BioNTech's updated Comirnaty for the 2026-27 season — approved for adults 65 and older and for people ages 5 through 64 with a high-risk condition — and shipping is starting immediately, in time for the fall wave. It is the fourth straight August the two companies have retooled, re-cleared, and re-shipped their mRNA shot.

Now put the two endpoints side by side, because the distance between them is the story. In 2022 the franchise sold $37.8 billion of vaccine and $18.9 billion of the pill Paxlovid — over half of a record roughly $100 billion revenue year, the first ever recorded by a drugmaker. The stock peaked near $61 in December 2021. This week, the entire COVID business, shot and pill combined, is forecast at about $4 billion for all of 2026: one-fourteenth the size. The numbers that follow answer one question — is the shrinking finished, and what does the stock actually hold once the engine no longer moves the company's totals?

The Engine

Name the machine first, because it is the same machine now running on far less fuel. Pfizer and BioNTech built the fastest variant-chasing operation pharma has ever seen: track the virus all winter, reformulate by spring, clear regulators by late August, ship before the fall surge. In 2021-22 that cadence ran against maximum demand — federal bulk contracts, a universal recommendation, and a public that lined up. About 75% of Americans received at least one dose of the early versions by early 2022. The product was not just profitable; it was treated like a utility.

The Hinge

The break came in fall 2023, the first season the shot sold through normal insurance channels instead of government contracts. Demand showed its real size, and Pfizer slashed its 2023 revenue outlook by $9 billion in October. That was the hinge: after it, the pandemic-era trajectory was impossible, and the company stopped forecasting a growth business and started absorbing a collapse — a collapse it is still absorbing in guidance today.

Then the regulators narrowed the customer base from the other side. For the 2025-26 season, the CDC dropped the universal recommendation in favor of individual-based decision-making, and the FDA cut the cleared population to seniors and high-risk people. This year's XFG version, chosen by the advisory panel in May, keeps that narrower shape. The federal guidance machinery itself has been unsettled: in the spring, a court halted the CDC's vaccine advisory committee, adding another layer of uncertainty to a rollout that already asks people to opt in.

Nothing about the machine broke. It reformulated, re-cleared, and re-shipped on schedule. What broke was the demand under it and the payer writing the check.

The Reversal, Measured

The demand data is the whole story now. About 23% of U.S. adults received the 2024-25 COVID shot — under half the 47% who got a flu shot that season — and CDC tracking put 2025-26 adult coverage around one in six. In the quarter that just ended, Comirnaty sales fell 34% year over year while Paxlovid fell 95%: the pill only sells when infection waves arrive, and this spring there wasn't one. Management cut its full-year COVID forecast by about $1 billion for that reason.

That is the reversal inside the reversal. The disease became the swing factor for the drug, and the drug stopped being the swing factor for the company. This year's approval went three ways — Moderna and Novavax cleared new shots beside Pfizer — all chasing the same one-in-six market.

What the Stock Actually Holds

Here the fate of the product splits from the fate of the shareholder. Pfizer raised its 2026 total-revenue guidance in the same quarter it cut COVID by $1 billion, because non-COVID products grew about 5% operationally and launched-and-acquired products grew 18%. The year now shapes up roughly flat against last year, with COVID reduced to a mid-single-digit slice of the guide: a seasonal floor rather than an engine.

The stock trades near $28 — up about 12% this year and near the top of its 52-week range — but still roughly 55% below its December 2021 peak, at about 13.5 times expected earnings for the year ahead and a dividend yield near 6.2%. At that valuation, the market is not paying for COVID growth. It is paying for the yield — and for what management does with the rest of the company: about $10 billion went to Metsera last November to buy into the obesity race.

That yield is where the durability test lives, and it is tighter than the headline suggests. Trailing free cash flow runs around $11 billion, while the dividend alone costs close to $10 billion a year. Covered — but with little slack, net debt near $52 billion, and a coming wave of patent expiries on older blockbusters.

The Break Condition

The early clue that read like background noise: Pfizer had already guided COVID down to about $4 billion weeks before this approval arrived. The headline was a non-event inside the company's own numbers, priced before the first truck left the warehouse. If adult uptake holds around one in six, the shot becomes a quiet, recurring cash floor. If it slips toward one in seven or eight, the floor falls with it, the guidance math gets harder, and a dividend that already swallows nearly all of free cash flow becomes the story investors should have been watching — not the shot that used to be the whole story.